It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
More than 120 speakers and 5,000 delegates are expected to attend
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Recommendation is based on pivotal data from the phase III POLARIX study
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
It recognizes the company's commitment to safeguarding sensitive data, protecting patient information
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Subscribe To Our Newsletter & Stay Updated
